|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2015-05-21 |
A randomised, double-blind, placebo-controlled, 3 parallel group efficacy and safety study of linagliptin 2.5 mg twice daily versus 5 mg once daily over 12 weeks as add-on therapy to a twice daily dosing regimen of metformin in patients with type 2 diabetes mellitus and insufficient glycaemic control
100 项与 Boehringer Ingelheim Korea Ltd. 相关的临床结果
0 项与 Boehringer Ingelheim Korea Ltd. 相关的专利(医药)
100 项与 Boehringer Ingelheim Korea Ltd. 相关的药物交易
100 项与 Boehringer Ingelheim Korea Ltd. 相关的转化医学